Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

AstraZeneca

AstraZeneca’s head and neck cancer treatment Imfinzi falls flat in Phase III trials

December 7, 2018
Medical Communications AstraZeneca, Cancer, oncology, phase III, treatment

AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer

November 16, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …

News
shutterstock_273326141

AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

November 13, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …

News
astrazeneca_building_white

AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study

November 12, 2018
Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Celgene, GSK, Novo Nordisk, politics, popular, top 10, vaccines

The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was …

News
nice_new_london_office_internal_2_8

NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis

November 9, 2018
Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma

Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …

News

AstraZeneca sells off three drugs in deal worth $350 million

November 6, 2018
Manufacturing and Production AstraZeneca, asthma, covis, deal, royalties

Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10

Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …

News
astrazeneca_plaque

AstraZeneca flogs two drug licenses in $922 million deal

October 31, 2018
Research and Development, Sales and Marketing AstraZeneca, pharma

AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

October 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …

News
astrazeneca_plaque

AstraZeneca halting UK investment due to Brexit uncertainty

October 15, 2018
Manufacturing and Production AstraZeneca, Le Monde, UK, brexit, no-deal

The Anglo-Swedish pharma firm AstraZeneca has suspended investment into the United Kingdom, due to the uncertainty surrounding Brexit. The firm’s …

News
astrazeneca_building_white

AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer

September 25, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …

News
astrazeneca-sign

AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients

September 24, 2018
Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma

AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings …

News
astrazeneca_plaque

AstraZeneca to increase presence in China

September 19, 2018
Research and Development AstraZeneca, China, alibaba, governemnt, tencent

The Anglo-Swedish multinational AstraZeneca is moving towards becoming a major healthcare provider in China as part of an effort to …

News
astrazeneca_plaque

FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)

September 17, 2018
Sales and Marketing AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases

AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025